AngioDynamics Inc. (ANGO)

21.24
0.14 0.65
NASDAQ : Health Technology
Prev Close 21.38
Open 21.37
Day Low/High 21.12 / 21.48
52 Wk Low/High 18.11 / 25.48
Volume 168.77K
Avg Volume 195.80K
Exchange NASDAQ
Shares Outstanding 37.22M
Market Cap 788.61M
EPS 1.60
P/E Ratio 50.45
Div & Yield N.A. (N.A)

Latest News

AngioDynamics Reports Fiscal 2019 Fourth Quarter And Full-Year Financial Results

AngioDynamics Reports Fiscal 2019 Fourth Quarter And Full-Year Financial Results

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced financial results for the fourth quarter of fiscal year 2019, which...

AngioDynamics To Report Fiscal 2019 Fourth Quarter And Full-Year Financial Results On July 10, 2019

AngioDynamics To Report Fiscal 2019 Fourth Quarter And Full-Year Financial Results On July 10, 2019

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the fourth quarter and...

AngioDynamics To Present At The Raymond James Life Sciences And MedTech Conference

AngioDynamics To Present At The Raymond James Life Sciences And MedTech Conference

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, will present...

AngioDynamics Completes Sale Of NAMIC® Fluid Management Portfolio To Medline Industries, Inc.

AngioDynamics Completes Sale Of NAMIC® Fluid Management Portfolio To Medline Industries, Inc.

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it closed the previously announced sale of its NAMIC ® fluid...

AngioDynamics To Ring NASDAQ Closing Bell To Celebrate The 15th Anniversary Of Its Listing On The Exchange

AngioDynamics To Ring NASDAQ Closing Bell To Celebrate The 15th Anniversary Of Its Listing On The Exchange

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that representatives of the Company will ring the NASDAQ Stock Market...

AngioDynamics Receives FDA Approval To Initiate Pilot Study For The Use Of NanoKnife® To Treat Prostate Cancer

AngioDynamics Receives FDA Approval To Initiate Pilot Study For The Use Of NanoKnife® To Treat Prostate Cancer

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that the United States Food and Drug Administration (FDA) approved the...

Relative Strength Alert For AngioDynamics

Relative Strength Alert For AngioDynamics

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

AngioDynamics Announces First Patient Enrolled In NanoKnife® DIRECT Clinical Study For The Treatment Of Stage III Pancreatic Cancer

AngioDynamics Announces First Patient Enrolled In NanoKnife® DIRECT Clinical Study For The Treatment Of Stage III Pancreatic Cancer

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced enrollment of the first patient in its NanoKnife ® Irreversible...

A Chinese E-Commerce Giant, an Office Furniture Maker and Other Stocks That Look Good Short

SIEB, JD, HNI, ANGO and EQBK all recently were downgraded by TheStreet's Quant Ratings.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: FORR, FRAC, JHG, QD, RDFN, RLI, SNBR, SUP Downgrades: ANGO, GSAT, RTIX, WCFB Initiations: FXNC Read on to get TheStreet Quant Ratings' detailed report:

RSI Alert: AngioDynamics (ANGO) Now Oversold

RSI Alert: AngioDynamics (ANGO) Now Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

AngioDynamics Announces Agreement To Sell NAMIC® Fluid Management Business To Medline Industries, Inc. For $167.5 Million

AngioDynamics Announces Agreement To Sell NAMIC® Fluid Management Business To Medline Industries, Inc. For $167.5 Million

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for oncology, vascular access, and peripheral vascular disease, today announced that it has entered into a definitive agreement to sell its NAMIC ®...

ANGO Makes Notable Cross Below Critical Moving Average

ANGO Makes Notable Cross Below Critical Moving Average

In trading on Wednesday, shares of AngioDynamics Inc crossed below their 200 day moving average of $21.63, changing hands as low as $21.24 per share. AngioDynamics Inc shares are currently trading down about 4.4% on the day.

AngioDynamics' DIRECT Clinical Study Receives Institutional Review Board Approval For The Treatment Of Stage III Pancreatic Cancer

AngioDynamics' DIRECT Clinical Study Receives Institutional Review Board Approval For The Treatment Of Stage III Pancreatic Cancer

AngioDynamics, Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that the Company received central Institutional Review Board (IRB)...

AngioDynamics Reports Fiscal 2019 Third Quarter Financial Results

AngioDynamics Reports Fiscal 2019 Third Quarter Financial Results

AngioDynamics, Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced financial results for the third quarter of fiscal year 2019, which...

AngioDynamics To Present At The Needham Healthcare Conference

AngioDynamics To Present At The Needham Healthcare Conference

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Michael C.

AngioDynamics Receives FDA Approval To Initiate NanoKnife® DIRECT Clinical Study For The Treatment Of Stage III Pancreatic Cancer

AngioDynamics Receives FDA Approval To Initiate NanoKnife® DIRECT Clinical Study For The Treatment Of Stage III Pancreatic Cancer

AngioDynamics, Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease and oncology, today announced that the United States Food and Drug Administration (FDA) approved the...

OARtrac® Radiation Dose Monitoring System Receives Expanded FDA Clearance For Electron Radiation Therapy

OARtrac® Radiation Dose Monitoring System Receives Expanded FDA Clearance For Electron Radiation Therapy

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease and oncology, today announced that the United States Food and Drug Administration (FDA) granted an...

AngioDynamics To Report Fiscal 2019 Third Quarter Financial Results On April 2, 2019

AngioDynamics To Report Fiscal 2019 Third Quarter Financial Results On April 2, 2019

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the third quarter of fiscal...

AngioDynamics Wins Patent Infringement Dispute With Bard

AngioDynamics Wins Patent Infringement Dispute With Bard

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease and oncology, today announced that the United States District Court for the District of Delaware, on...

AngioDynamics Breaks Below 200-Day Moving Average - Notable For ANGO

AngioDynamics Breaks Below 200-Day Moving Average - Notable For ANGO

In trading on Wednesday, shares of AngioDynamics Inc crossed below their 200 day moving average of $21.48, changing hands as low as $21.19 per share. AngioDynamics Inc shares are currently trading down about 1.7% on the day.

AngioDynamics To Present At The Barclays Global Healthcare Conference

AngioDynamics To Present At The Barclays Global Healthcare Conference

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, and Michael C.

Bullish Two Hundred Day Moving Average Cross - ANGO

Bullish Two Hundred Day Moving Average Cross - ANGO

In trading on Friday, shares of AngioDynamics Inc crossed above their 200 day moving average of $21.15, changing hands as high as $21.33 per share. AngioDynamics Inc shares are currently trading up about 1.4% on the day.

AngioDynamics Reports Fiscal 2019 Second Quarter Financial Results

AngioDynamics Reports Fiscal 2019 Second Quarter Financial Results

AngioDynamics, Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced financial results for the second quarter of fiscal year 2019, which...

AngioDynamics To Present At The J.P. Morgan Healthcare Conference

AngioDynamics To Present At The J.P. Morgan Healthcare Conference

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, and Michael C.

AngioDynamics To Report Fiscal 2019 Second Quarter Financial Results On January 4, 2019

AngioDynamics To Report Fiscal 2019 Second Quarter Financial Results On January 4, 2019

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the second quarter of fiscal...

AngioDynamics (ANGO) Shares Cross Below 200 DMA

AngioDynamics (ANGO) Shares Cross Below 200 DMA

In trading on Monday, shares of AngioDynamics Inc crossed below their 200 day moving average of $20.63, changing hands as low as $20.51 per share. AngioDynamics Inc shares are currently trading down about 1.3% on the day.

ANGO Makes Notable Cross Below Critical Moving Average

ANGO Makes Notable Cross Below Critical Moving Average

In trading on Monday, shares of AngioDynamics Inc crossed below their 200 day moving average of $19.93, changing hands as low as $19.91 per share. AngioDynamics Inc shares are currently trading down about 1% on the day.

TheStreet Quant Rating: B (Buy)